Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_2
2
40%
Ph phase_3
2
40%
Ph phase_4
1
20%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Other(1)

Detailed Status

Completed4
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (40.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

unknown120%
completed480%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

NCT00098241
completedphase_2

Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

NCT00504543
completedphase_2

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

NCT01596062
completedphase_3

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

NCT01079143
unknownphase_4

Efficacy of Certican® in Combination With Myfortic® in Renal

NCT01399242

Clinical Trials (5)

Showing 5 of 5 trials
NCT00098241Phase 3

Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients

Completed
NCT00504543Phase 2

Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients

Completed
NCT01596062Phase 2

Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)

Completed
NCT01079143Phase 3

Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients

Completed
NCT01399242Phase 4

Efficacy of Certican® in Combination With Myfortic® in Renal

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5